Micropartículas de xilana contendo mesalazina visando a liberação no cólon
Xylan is an important biopolymer that can be extracted from several agrowastes in the world and has been receiving a great attention on the production of colon drug delivery systems. This polymer could pass through the digestive tract unchanged. Its complex structure requires enzymes that are prod...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | doctoralThesis |
| Idioma: | pt_BR |
| Publicado em: |
Universidade Federal do Rio Grande do Norte
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/handle/123456789/32219 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| id |
ri-123456789-32219 |
|---|---|
| record_format |
dspace |
| institution |
Repositório Institucional |
| collection |
RI - UFRN |
| language |
pt_BR |
| topic |
Mesalazina Biopolímero Hemicelulose Sistemas de liberação de fármacos DDsolver |
| spellingShingle |
Mesalazina Biopolímero Hemicelulose Sistemas de liberação de fármacos DDsolver Urtiga, Silvana Cartaxo da Costa Micropartículas de xilana contendo mesalazina visando a liberação no cólon |
| description |
Xylan is an important biopolymer that can be extracted from several agrowastes in the world and has been receiving a great attention on the production
of colon drug delivery systems. This polymer could pass through the digestive
tract unchanged. Its complex structure requires enzymes that are produced
specifically by the human colonic microflora, which makes it an interesting raw
material to produce targeted drug delivery systems. The aim of this work was to
produce xylan-based delivery systems loaded of mesalamine as a drug model.
Xylan was extracted from corn cobs and posteriorly used to produce
mesalamine-loaded xylan microparticles (XMP5-ASA) by cross-linking
polymerization using a non-hazardous cross-linking agent. The microparticles
were characterized by thermal analysis (DSC/TG), X-ray diffraction (XRD),
infrared spectroscopy (FTIR-ATR) and scanning electron microscopy (SEM). A
comparative study of the in vitro drug release from XMP5-ASA and from gastroresistant capsules filled with XMP5-ASA (XMPCAP5-ASA) or 5-ASA was also
performed. FTIR-ATR, XRD and DSC/TG studies indicated no interactions
among the components of the formulation that could interfere on the drug
characteristics and that the drug was molecularly dispersed into the
microparticles, enhancing the drug stability. The microparticles presented a
spherical shape with a mean diameter size of 12.66 m ± 1.01 and 14.64 m ±
0.5 μm for XMP and XMP5-ASA, respectively. The entrapment efficiency for
XMP5-ASA was 65.41 ± 3.9 %.The release studies showed that XMPCAP5-
ASA allowed more efficient drug retention in the simulated gastric fluid with a
prolonged drug release lasting up to 24 h. XMPCAP5-ASA retained
approximately 48 % of its drug content after 6 h on the drug release assay.
Therefore, the encapsulation of 5-ASA into xylan microparticles together with
gastro-resistant capsules allowed a drug-controlled release at different
simulated gastrointestinal medium. |
| author2 |
Egito, Eryvaldo Socrates Tabosa do |
| author_facet |
Egito, Eryvaldo Socrates Tabosa do Urtiga, Silvana Cartaxo da Costa |
| format |
doctoralThesis |
| author |
Urtiga, Silvana Cartaxo da Costa |
| author_sort |
Urtiga, Silvana Cartaxo da Costa |
| title |
Micropartículas de xilana contendo mesalazina visando a liberação no cólon |
| title_short |
Micropartículas de xilana contendo mesalazina visando a liberação no cólon |
| title_full |
Micropartículas de xilana contendo mesalazina visando a liberação no cólon |
| title_fullStr |
Micropartículas de xilana contendo mesalazina visando a liberação no cólon |
| title_full_unstemmed |
Micropartículas de xilana contendo mesalazina visando a liberação no cólon |
| title_sort |
micropartículas de xilana contendo mesalazina visando a liberação no cólon |
| publisher |
Universidade Federal do Rio Grande do Norte |
| publishDate |
2021 |
| url |
https://repositorio.ufrn.br/handle/123456789/32219 |
| work_keys_str_mv |
AT urtigasilvanacartaxodacosta microparticulasdexilanacontendomesalazinavisandoaliberacaonocolon |
| _version_ |
1773962492534325248 |
| spelling |
ri-123456789-322192021-04-18T09:07:03Z Micropartículas de xilana contendo mesalazina visando a liberação no cólon Urtiga, Silvana Cartaxo da Costa Egito, Eryvaldo Socrates Tabosa do http://lattes.cnpq.br/8942021313255546 http://lattes.cnpq.br/6907806915889763 Silva Júnior, Arnóbio Antônio da http://lattes.cnpq.br/2593509584288129 Oliveira, Elquio Eleamen http://lattes.cnpq.br/9506411475317395 Reynaud, Franceline http://lattes.cnpq.br/2561590161798118 Xavier Júnior, Francisco Humberto http://lattes.cnpq.br/8704684733554389 Giordani, Raquel Brandt http://lattes.cnpq.br/5032750980466610 Mesalazina Biopolímero Hemicelulose Sistemas de liberação de fármacos DDsolver Xylan is an important biopolymer that can be extracted from several agrowastes in the world and has been receiving a great attention on the production of colon drug delivery systems. This polymer could pass through the digestive tract unchanged. Its complex structure requires enzymes that are produced specifically by the human colonic microflora, which makes it an interesting raw material to produce targeted drug delivery systems. The aim of this work was to produce xylan-based delivery systems loaded of mesalamine as a drug model. Xylan was extracted from corn cobs and posteriorly used to produce mesalamine-loaded xylan microparticles (XMP5-ASA) by cross-linking polymerization using a non-hazardous cross-linking agent. The microparticles were characterized by thermal analysis (DSC/TG), X-ray diffraction (XRD), infrared spectroscopy (FTIR-ATR) and scanning electron microscopy (SEM). A comparative study of the in vitro drug release from XMP5-ASA and from gastroresistant capsules filled with XMP5-ASA (XMPCAP5-ASA) or 5-ASA was also performed. FTIR-ATR, XRD and DSC/TG studies indicated no interactions among the components of the formulation that could interfere on the drug characteristics and that the drug was molecularly dispersed into the microparticles, enhancing the drug stability. The microparticles presented a spherical shape with a mean diameter size of 12.66 m ± 1.01 and 14.64 m ± 0.5 μm for XMP and XMP5-ASA, respectively. The entrapment efficiency for XMP5-ASA was 65.41 ± 3.9 %.The release studies showed that XMPCAP5- ASA allowed more efficient drug retention in the simulated gastric fluid with a prolonged drug release lasting up to 24 h. XMPCAP5-ASA retained approximately 48 % of its drug content after 6 h on the drug release assay. Therefore, the encapsulation of 5-ASA into xylan microparticles together with gastro-resistant capsules allowed a drug-controlled release at different simulated gastrointestinal medium. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES A xilana é um importante biopolímero que pode ser extraído de vários resíduos agrícolas e tem recebido grande atenção no desenvolvimento de sistemas de liberação de fármaco para o cólon. Esse polímero tem a capacidade de passar pelo trato digestivo inalterado e sua estrutura complexa requer enzimas que são produzidas especificamente pela microflora colônica humana, o que o torna uma matéria-prima interessante na produção de sistemas de liberação sítio específicas de fármacos. O objetivo desta tese foi produzir sistemas terapêuticos a base de xilana contendo mesalazina como molécula modelo para liberação na porção intestinal do cólon. A xilana foi extraída do sabugo de milho e posteriormente utilizada para produzir as micropartículas contendo mesalazina (XMP5-ASA) através da reticulação polimérica utilizando um agente de reticulação atóxico. As micropartículas foram caracterizadas por análise térmica (DSC/TG), difração de raios-X (DRX), espectroscopia de infravermelho (FTIR-ATR) e microscopia eletrônica de varredura (MEV). A liberação in vitro do 5-ASA das XMP5-ASA e de cápsulas gastro-resistentes contendo XMP5-ASA (XMPCAP5-ASA) foram realizadas. FTIR-ATR, DRX e DSC/TG indicaram que não houve nenhuma interação entre os componentes da formulação que afetasse as características físicas do fármaco, que se encontrava molecularmente disperso nas micropartículas, melhorando sua estabilidade. As micropartículas apresentaram formato esférico com diâmetro médio de 12,66 m ± 1,01 e 14,64 m ± 0,5 para XMP e XMP5-ASA, respectivamente. A eficiência de encapsulação para XMP5-ASA foi de 65,41 ± 3,9%. Os estudos de liberação mostraram que o XMPCAP5-ASA permitiu uma retenção mais eficiente do fármaco no fluido gástrico simulado e uma liberação prolongada por 24 horas. XMPCAP5-ASA reteve aproximadamente 48% de seu conteúdo de fármaco após 6 h no ensaio de liberação. Portanto, o encapsulamento de 5-ASA em micropartículas de xilana associada com cápsulas gastro-resistentes permitiram um melhor controle da liberação do fármaco em diferentes meios gastrointestinais simulados. 2021-04-14T23:21:44Z 2021-04-14T23:21:44Z 2020-12-18 doctoralThesis URTIGA, Silvana Cartaxo da Costa. Micropartículas de xilana contendo mesalazina visando a liberação no cólon. 2020. 37f. Tese (Doutorado em Ciências da Saúde) - Centro de Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal, 2020. https://repositorio.ufrn.br/handle/123456789/32219 pt_BR Acesso Aberto application/pdf Universidade Federal do Rio Grande do Norte Brasil UFRN PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE |